Hafslund Nycomed's non-US contrast agent sales up 20%
This article was originally published in Clinica
Hafslund Nycomed, the Norwegian pharmaceutical and contrast agent manufacturer, has reported 20% higher contrast agent sales through its distribution network outside the US in 1994. In the US the company says competition in the diagnostic imaging market has intensified but the company's market share has been maintained in the X-ray field and increased within MRI. Last July, Nycomed boosted its contrast agent division with the purchase of Sterling Winthrop's imaging business from Sanofi (see Clinica No 610, p 14) and achieved a leading position in this market.